A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2019
Price : $35 *
At a glance
- Drugs Baltaleucel-T (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- Acronyms CITADEL
- Sponsors Cell Medica
- 10 Jan 2019 Status changed from recruiting to discontinued.
- 12 Dec 2017 Results (n=11, data cut off:31 Jul 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 07 Apr 2017 Planned End Date changed from 1 Dec 2018 to 1 Sep 2019.